In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Investing.com -- Novo Nordisk (NYSE: NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

More than a billion people now have obesity worldwide, according to the WHO, and around 70% of them live in low and ...

First, he landed his role in "Modern Family," a critically acclaimed ABC sitcom that went on for 11 seasons and catapulted ...

Kyle Richards’s daughter, Sophia Umansky, shared alarming footage of her hair loss after rapidly losing weight with the help ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

On this week’s episode of the Readout LOUD, we review President Trump’s first 100 days, the return of biotech M&A, strong ...